Kali Therapeutics, Inc.

Kali Therapeutics is a biotechnology company focused on developing next-generation biologics, specifically trispecific T-cell engagers (TCEs), for the treatment of autoimmune diseases and B-cell malignancies. The company utilizes a proprietary CD3 masking platform designed to decouple potent B-cell cytotoxicity from systemic cytokine release, aiming to improve the therapeutic index and safety profile of its candidates. The company is currently advancing a pipeline of trispecific antibodies, including its lead candidate KT501, which is in clinical development for rheumatoid arthritis. In March 2026, Kali Therapeutics entered into a significant worldwide exclusive licensing agreement with Sanofi for KT501, valued at up to $1.2 billion in upfront, near-term, and milestone payments.